An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge
Assessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Emerging Microbes and Infections |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2447619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591111774797824 |
|---|---|
| author | Entao Li Qiyuan Yang Wenyu Xie Qizan Gong Xiaoping Guo Jinge Zhou Jiachen Zhang Xia Chuai Yucai Wang Sandra Chiu |
| author_facet | Entao Li Qiyuan Yang Wenyu Xie Qizan Gong Xiaoping Guo Jinge Zhou Jiachen Zhang Xia Chuai Yucai Wang Sandra Chiu |
| author_sort | Entao Li |
| collection | DOAJ |
| description | Assessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including the induction of MPXV A35/B6/A29/M1-specific IgG antibodies, VACV neutralizing antibodies and activated cytotoxic CD8+T cells, which provides 100% protection against lethal VACV challenge even at 280 days after the first vaccination. Our results provide critical insights for orthopoxvirus vaccine development. |
| format | Article |
| id | doaj-art-8bdb02e125d644bc8808086c226e31c1 |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-8bdb02e125d644bc8808086c226e31c12025-01-23T04:05:05ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512025-12-0114110.1080/22221751.2024.2447619An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challengeEntao Li0Qiyuan Yang1Wenyu Xie2Qizan Gong3Xiaoping Guo4Jinge Zhou5Jiachen Zhang6Xia Chuai7Yucai Wang8Sandra Chiu9Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, ChinaDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaAssessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including the induction of MPXV A35/B6/A29/M1-specific IgG antibodies, VACV neutralizing antibodies and activated cytotoxic CD8+T cells, which provides 100% protection against lethal VACV challenge even at 280 days after the first vaccination. Our results provide critical insights for orthopoxvirus vaccine development.https://www.tandfonline.com/doi/10.1080/22221751.2024.2447619 |
| spellingShingle | Entao Li Qiyuan Yang Wenyu Xie Qizan Gong Xiaoping Guo Jinge Zhou Jiachen Zhang Xia Chuai Yucai Wang Sandra Chiu An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge Emerging Microbes and Infections |
| title | An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| title_full | An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| title_fullStr | An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| title_full_unstemmed | An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| title_short | An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| title_sort | mpox quadrivalent mrna vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2447619 |
| work_keys_str_mv | AT entaoli anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT qiyuanyang anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT wenyuxie anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT qizangong anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT xiaopingguo anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT jingezhou anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT jiachenzhang anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT xiachuai anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT yucaiwang anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT sandrachiu anmpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT entaoli mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT qiyuanyang mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT wenyuxie mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT qizangong mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT xiaopingguo mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT jingezhou mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT jiachenzhang mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT xiachuai mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT yucaiwang mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge AT sandrachiu mpoxquadrivalentmrnavaccineelicitssustainedandprotectiveimmunityinmiceagainstlethalvacciniaviruschallenge |